• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

终末期肾病患者择期冠状动脉球囊血管成形术后再狭窄:一项使用定量冠状动脉造影的病例对照研究。

Restenosis after elective coronary balloon angioplasty in patients with end stage renal disease: a case-control study using quantitative coronary angiography.

作者信息

Schoebel F C, Gradaus F, Ivens K, Heering P, Jax T W, Grabensee B, Strauer B E, Leschke M

机构信息

Medizinische Klinik, Heinrich-Heine Universität Düsseldorf, Germany.

出版信息

Heart. 1997 Oct;78(4):337-42. doi: 10.1136/hrt.78.4.337.

DOI:10.1136/hrt.78.4.337
PMID:9404246
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1892250/
Abstract

OBJECTIVE

To assess the rate of angiographic restenosis in patients with end stage renal disease after elective coronary angioplasty.

DESIGN

A retrospective case-control study of 20 patients with end stage renal disease and 20 sex and age matched controls without renal disease, who had undergone primarily successful coronary angioplasty. Control coronary angiography was performed regardless of worsening or renewed incidence of anginal symptoms.

MAIN OUTCOME MEASURES

Group comparison of coronary morphology, as evaluated by quantitative coronary angiography, and of cardiovascular risk factors.

RESULTS

The rate of angiographic restenosis was 60% in patients with renal disease and 35% in controls. In patients with end stage renal disease the following differences (mean (SD) were found versus controls: raised plasma fibrinogen (483 (101) v 326 (62) mg/dl, p < 0.001); raised plasma triglyceride (269 (163) v 207 (176) mg/dl, p < 0.01); smaller diameter of the coronary reference segment (2.59 (0.87) v 2.90 (0.55) mm, p < 0.10); smaller minimum luminal diameter of the dilated stenosis (0.77 (0.46) v 0.97 (0.27) mm, p < 0.05). Discriminant analysis showed that minimum luminal diameter before angioplasty (r = -0.79) and fibrinogen (r = +0.34) had the highest statistical association with restenosis.

CONCLUSIONS

The high rate of angiographic restenosis in patients with end stage renal disease seems to be related to the size of the vessel dilated and to an increased prothrombotic risk, as indicated by higher fibrinogen concentrations.

摘要

目的

评估终末期肾病患者择期冠状动脉成形术后血管造影再狭窄的发生率。

设计

一项回顾性病例对照研究,研究对象为20例终末期肾病患者和20例年龄及性别匹配的无肾病对照者,这些患者均接受了首次成功的冠状动脉成形术。无论心绞痛症状是否加重或复发,均进行对照冠状动脉造影。

主要观察指标

通过定量冠状动脉造影评估的冠状动脉形态及心血管危险因素的组间比较。

结果

肾病患者血管造影再狭窄发生率为60%,对照组为35%。终末期肾病患者与对照组相比,存在以下差异(均值(标准差)):血浆纤维蛋白原升高(483(101)对326(62)mg/dl,p<0.001);血浆甘油三酯升高(269(163)对207(176)mg/dl,p<0.01);冠状动脉参考节段直径较小(2.59(0.87)对2.90(0.55)mm,p<0.10);扩张狭窄处的最小管腔直径较小(0.77(0.46)对0.97(0.27)mm,p<0.05)。判别分析显示,成形术前最小管腔直径(r = -0.79)和纤维蛋白原(r = +0.34)与再狭窄的统计学关联最强。

结论

终末期肾病患者血管造影再狭窄发生率高似乎与扩张血管的大小以及纤维蛋白原浓度升高所提示的血栓形成风险增加有关。

相似文献

1
Restenosis after elective coronary balloon angioplasty in patients with end stage renal disease: a case-control study using quantitative coronary angiography.终末期肾病患者择期冠状动脉球囊血管成形术后再狭窄:一项使用定量冠状动脉造影的病例对照研究。
Heart. 1997 Oct;78(4):337-42. doi: 10.1136/hrt.78.4.337.
2
[Rate of restenosis after PTCA in patients with terminal renal failure. A quantitative coronary angiography study].[终末期肾衰竭患者经皮冠状动脉腔内血管成形术后再狭窄率。一项定量冠状动脉血管造影研究]
Z Kardiol. 1997 May;86(5):373-9. doi: 10.1007/s003920050071.
3
Influence of serum cholesterol and cholesterol subfractions on restenosis after successful coronary angioplasty. A quantitative angiographic analysis of 3336 lesions.血清胆固醇及胆固醇亚组分对冠状动脉成形术成功后再狭窄的影响。对3336处病变的定量血管造影分析。
Circulation. 1994 Nov;90(5):2267-79. doi: 10.1161/01.cir.90.5.2267.
4
Serum lipids and restenosis after successful percutaneous transluminal coronary angioplasty. Ichilov Magnesium Study Group.经皮腔内冠状动脉成形术成功后的血清脂质与再狭窄。伊奇洛夫镁研究小组。
Am J Cardiol. 1994 Jun 15;73(16):1154-8. doi: 10.1016/0002-9149(94)90173-2.
5
Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group.冠状动脉支架置入术与球囊血管成形术治疗初次球囊血管成形术后再狭窄的比较。再狭窄支架研究组。
N Engl J Med. 1998 Dec 3;339(23):1672-8. doi: 10.1056/NEJM199812033392304.
6
Association of an acute reduction in lipoprotein(a) with coronary artery restenosis after percutaneous transluminal coronary angioplasty.经皮腔内冠状动脉成形术后脂蛋白(a)急性降低与冠状动脉再狭窄的关联。
Circulation. 1997 Jul 1;96(1):166-73.
7
Impact of end-stage renal disease on clinical and angiographic outcomes after coronary stenting.终末期肾病对冠状动脉支架置入术后临床及血管造影结果的影响。
Am J Cardiol. 2000 Sep 1;86(5):485-9. doi: 10.1016/s0002-9149(00)00998-x.
8
Clinical outcome following coronary angioplasty in dialysis patients: a case-control study in the era of coronary stenting.透析患者冠状动脉血管成形术后的临床结局:冠状动脉支架置入时代的一项病例对照研究
Heart. 2001 May;85(5):556-60. doi: 10.1136/heart.85.5.556.
9
Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group.洛伐他汀对冠状动脉成形术后再狭窄无效。洛伐他汀再狭窄试验研究组。
N Engl J Med. 1994 Nov 17;331(20):1331-7. doi: 10.1056/NEJM199411173312002.
10
Angiographic progression of coronary artery disease in patients with end-stage renal disease.终末期肾病患者冠状动脉疾病的血管造影进展
Nephrol Dial Transplant. 2001 Jun;16(6):1198-202. doi: 10.1093/ndt/16.6.1198.

引用本文的文献

1
Renal Impairment and Prognosis of Patients with Atrial Fibrillation Undergoing Coronary Intervention - The AFCAS Trial.冠状动脉介入治疗的心房颤动患者的肾功能损害与预后——AFCAS试验
PLoS One. 2015 Jun 1;10(6):e0128492. doi: 10.1371/journal.pone.0128492. eCollection 2015.
2
The impact of renal impairment on long-term safety and effectiveness of drug-eluting stents.肾功能损害对药物洗脱支架长期安全性和有效性的影响。
PLoS One. 2014 Sep 3;9(9):e106450. doi: 10.1371/journal.pone.0106450. eCollection 2014.
3
Thrombosis in the uremic milieu--emerging role of "thrombolome".尿毒症环境中的血栓形成——“血栓形成组”的新作用
Semin Dial. 2015 Mar-Apr;28(2):198-205. doi: 10.1111/sdi.12255. Epub 2014 Jun 24.
4
An update on coronary artery disease and chronic kidney disease.冠状动脉疾病与慢性肾脏病的最新进展
Int J Nephrol. 2014;2014:767424. doi: 10.1155/2014/767424. Epub 2014 Mar 10.
5
Cardiac survival after pre-emptive coronary angiography in transplant patients and those awaiting transplantation.移植患者和等待移植患者的抢先冠状动脉造影后的心脏存活。
Clin J Am Soc Nephrol. 2011 Aug;6(8):1912-9. doi: 10.2215/CJN.08680910. Epub 2011 Jul 7.
6
Revascularization options in patients with chronic kidney disease.慢性肾病患者的血运重建选择
Tex Heart Inst J. 2010;37(1):9-18.
7
Myocardial revascularization in patients with end-stage renal disease: comparison of percutaneous transluminal coronary angioplasty and coronary artery bypass grafting.终末期肾病患者的心肌血运重建:经皮腔内冠状动脉成形术与冠状动脉旁路移植术的比较
Int Urol Nephrol. 2001;32(4):717-23. doi: 10.1023/a:1015067611958.
8
Clinical outcome following coronary angioplasty in dialysis patients: a case-control study in the era of coronary stenting.透析患者冠状动脉血管成形术后的临床结局:冠状动脉支架置入时代的一项病例对照研究
Heart. 2001 May;85(5):556-60. doi: 10.1136/heart.85.5.556.

本文引用的文献

1
[Rapid physiological coagulation method in determination of fibrinogen].[快速生理凝血法测定纤维蛋白原]
Acta Haematol. 1957 Apr;17(4):237-46. doi: 10.1159/000205234.
2
Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy.传统心血管危险因素对接受肾脏替代治疗的糖尿病患者冠状动脉疾病预测的相关性。
Nephrol Dial Transplant. 1997 Jun;12(6):1187-91. doi: 10.1093/ndt/12.6.1187.
3
Activation of the fibrinolytic system in patients with coronary artery disease and hyperfibrinogenemia.冠状动脉疾病和高纤维蛋白原血症患者纤溶系统的激活。
Thromb Haemost. 1997 May;77(5):970-4.
4
Long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris: a randomized dose-response trial.终末期冠状动脉疾病和难治性心绞痛患者的长期间歇性尿激酶治疗:一项随机剂量反应试验。
J Am Coll Cardiol. 1996 Mar 1;27(3):575-84. doi: 10.1016/0735-1097(95)00494-7.
5
The three processes leading to post PTCA restenosis: dependence on the lesion substrate.导致经皮冠状动脉腔内血管成形术(PTCA)后再狭窄的三个过程:取决于病变基质。
Thromb Haemost. 1995 Jul;74(1):552-9.
6
A maximum confidence approach for measuring progression and regression of coronary artery disease in clinical trials.一种用于在临床试验中测量冠状动脉疾病进展和消退的最大置信度方法。
Circulation. 1993 Mar;87(3 Suppl):II66-73.
7
Variability in measures of coronary lumen dimensions using quantitative coronary angiography.使用定量冠状动脉造影术测量冠状动脉管腔尺寸时的变异性。
J Am Coll Cardiol. 1993 Oct;22(4):1068-74. doi: 10.1016/0735-1097(93)90417-y.
8
Fibrinogen plasma levels as a marker of thrombin activation: new insights on the role of fibrinogen as a cardiovascular risk factor.血浆纤维蛋白原水平作为凝血酶激活的标志物:关于纤维蛋白原作为心血管危险因素作用的新见解。
Thromb Haemost. 1994 May;71(5):593-5.
9
A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.冠状动脉支架置入术与球囊血管成形术治疗冠状动脉疾病的随机对照研究。支架再狭窄研究组。
N Engl J Med. 1994 Aug 25;331(8):496-501. doi: 10.1056/NEJM199408253310802.
10
A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group.冠状动脉疾病患者中球囊扩张式支架植入术与球囊血管成形术的比较。贝内斯特恩研究小组。
N Engl J Med. 1994 Aug 25;331(8):489-95. doi: 10.1056/NEJM199408253310801.